Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K, Geurts BS, Zeverijn LJ, van der Noort V, Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML, Jalving M, Gietema JA, Devriese LA, Labots M, Barjesteh van Waalwijk van Doorn-Khosrovani S, Smit EF, Bloemendal HJ. Verkerk K, et al. Among authors: gietema ja. Lancet Reg Health Eur. 2024 Mar 5;39:100875. doi: 10.1016/j.lanepe.2024.100875. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38464480 Free PMC article.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. Hoekstra R, et al. Among authors: gietema ja. J Clin Oncol. 2005 Aug 1;23(22):5188-97. doi: 10.1200/JCO.2005.05.013. J Clin Oncol. 2005. PMID: 16051960 Clinical Trial.
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG. Eskens FA, et al. Among authors: gietema ja. Br J Cancer. 2008 Jan 15;98(1):80-5. doi: 10.1038/sj.bjc.6604108. Epub 2007 Nov 20. Br J Cancer. 2008. PMID: 18026190 Free PMC article. Clinical Trial.
Metformin: taking away the candy for cancer?
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Jalving M, et al. Among authors: gietema ja. Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Eur J Cancer. 2010. PMID: 20656475 Review.
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA. van der Veldt AA, et al. Among authors: gietema j. Clin Cancer Res. 2011 Feb 1;17(3):620-9. doi: 10.1158/1078-0432.CCR-10-1828. Epub 2010 Nov 19. Clin Cancer Res. 2011. PMID: 21097692
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Vermaat JS, et al. Among authors: gietema ja. Eur Urol. 2012 Oct;62(4):685-95. doi: 10.1016/j.eururo.2012.01.020. Epub 2012 Jan 23. Eur Urol. 2012. PMID: 22285764
227 results